ABSTRACT
Full genome sequences are increasingly used to track the geographic spread and transmission dynamics of viral pathogens. Here, with a focus on Israel, we sequenced 212 SARS-CoV-2 sequences and use them to perform a comprehensive analysis to trace the origins and spread of the virus. A phylogenetic analysis including thousands of globally sampled sequences allowed us to infer multiple independent introductions into Israel, followed by local transmission. Returning travelers from the U.S. contributed dramatically more to viral spread relative to their proportion in incoming infected travelers. Using phylodynamic analysis, we estimated that the basic reproduction number of the virus was initially around ~2.0-2.6, dropping by two-thirds following the implementation of social distancing measures. A comparison between reported and model-estimated case numbers indicated high levels of transmission heterogeneity in SARS-CoV-2 spread, with between 1-10% of infected individuals resulting in 80% of secondary infections. Overall, our findings underscore the ability of this virus to efficiently transmit between and within countries, as well as demonstrate the effectiveness of social distancing measures for reducing its spread.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the Israeli Science Foundation (1333/16) and by a generous donation from the Milner foundation and from AppFlyer. This study was supported in part by a fellowship to DM, TK and OT from the Edmond J. Safra Center for Bioinformatics at Tel-Aviv University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
An exemption from institutional review board approval was determined by the Israeli Ministry of Health as part of an active epidemiological investigation, based on use of anonymous data only and no medical intervention. The study was further approved by the Tel-Aviv University ethics committee (approval 0001274-1).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Co-equal authorship
Data Availability
The assembled SARS-CoV-2 genomes (consensus sequences) were uploaded to GISAID (Table S1). Submission of the raw sequencing data to Sequence Read Archive (SRA) is pending. Code for phylodynamic analysis and model XML configuration, as well as scripts to analyze outputs are available on github.
